Cylembio

News

IO Biotech's cancer vaccine Cylembio failed to hit the mark in a phase 3 melanoma trial – but the company hopes to file for approval regardless.

News

Merck's drug for tumours associated with rare disease neurofibromatosis type 1, Ezmekly, has been cleared for NHS use in children as young as two.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.